NERV beat EPS expectations by 54.19%
May 13, 2025, 10:35 PM
0.00%
What does NERV do
Minerva Neurosciences, a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focuses on developing treatments for central nervous system diseases, including roluperidone for schizophrenia and MIN-301 for Parkinson's disease. Founded in 2014, it employs 9 people and co-developed seltorexant for insomnia and major depressive disorder.
Minerva Neurosciences (NERV) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Minerva Neurosciences's actual EPS was -$0.50, beating the estimate of -$1.09 per share, resulting in a 54.19% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.